MCP-1 -2518 A/G gene polymorphism is associated with blood pressure in ischemic heart disease asymptomatic subjects

Bratislava Medical Journal

Volumn 111, Issue 8, 2010, Pages 420-425

  Penz, P ^a   Bucova, M ^a   Lietava, J ^a   Blazicek, P ^b   Paulovicova, E ^c   Mrazek, F ^d   Bernadic, M ^a   Buckingham, T A ^a   Petrek, M ^d  

^a Bratislava   (Slovakia)

^b Hospital of Ministry of Defence   (Slovakia)

^c INSTITUTE OF CHEMISTRY   (Slovakia)

^d PALACKÝ UNIVERSITY   (Czech Republic)

Author keywords

Cardiovascular risk; CRP; Cytokine polymorphism.; Hypertension; Inflammation; Ischemic heart disease; MCP 1

Indexed keywords

MONOCYTE CHEMOTACTIC PROTEIN 1;

ADULT; ARTICLE; BLOOD PRESSURE; FEMALE; GENETICS; GENOTYPE; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; BLOOD PRESSURE; CHEMOKINE CCL2; FEMALE; GENOTYPE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 77956916447     PISSN: 00069248     EISSN: 13360345     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Eriksson EE. Mechanisms of leukocyte recruitment to atherosclerotic lesions: future prospects. Curr Opin Lipidol 2004; 15: 553-558.
2. Viedt C, Vogel J, Athanasiou T et al. Monocyte chemoattractant protein-1 induces proliferation and interleukin-6 production in human smooth muscle cells by differential activation of nuclear factor-kap-paB and activator protein-1. Arterioscler Thromb Vase Biol 2002; 22: 914-920.
3. Gu L, Okada Y, Clinton SK et al. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol Cell 1998; 2: 275-281.
4. Aiello RJ, Bourassa PA, Lindsey S et al. Monocyte chemoattrac tant protein-1 accelerates atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vase Biol 1999; 19: 1518-1525.
5. de Lemos JA, Morrow DA, Sabatine MS et al. Association between plasma levels of monocyte chemoattractant protein-1 and long-term clinical outcomes in patients with acute coronary syndromes. Circulation 2003; 107: 690-695.
6. Cipollone F, Marini M, Fazia M et al. Elevated circulating levels of monocyte chemoattractant protein-1 in patients with restenosis after coronary angioplasty. Arterioscler Thromb Vase Biol 2001; 21: 327-334.
7. Deo R, Khera A, McGuire DK et al. Association among plasma levels of monocyte chemoattractant protein-1, traditional cardiovascular risk factors, and subclinical atherosclerosis. J Am Coll Cardiol 2004; 44: 1812-1818.
8. McDermott DH, Yang Q, Kathiresan S et al. CCL2 polymorphis ms are associated with serum monocyte chemoattractant protein-1 levels and myocardial infarction in the Framingham Heart Study. Circulation 2005; 112: 1113-1120.
9. Petrkova J, Cermakova Z, Drabek J, Lukl J, Petrek M. CC che-mokine receptor (CCR)2 polymorphism in Czech patients with myocardial infarction. Immunol Lett 2003; 88: 53-55.
10. Bucova M, Lietava J, Mrazek F et al. Association of chronic stable angina pectoris with MCP-1-2518 A/G single nucleotide polymorphism in the Slovak population. Clin Chim Acta 2008; 392: 71-72.
11. Bucova M, Lietava J, Mrazek F et al. The MCP-1 -2518 (A/G) single nucleotide polymorphism is associated with ischemic heart dise ase and myocardial infarction in men in the Slovak population. Bratisl Lek Listy 2009; 110: 385-389.
12. Bucova M, Lietava J, Penz P et al. Association of MCP-1 -2518 A/G single nucleotide polymorphism with the serum level of CRP in Slovak patients with ischemic heart disease, angina pectoris, and hypertension. Mediators Inflamm 2009; 2009: 390951.
13. Yasui N, Kajimoto K, Sumiya T, Okuda T, Iwai N. The monocyte chemotactic protein-1 gene may contribute to hypertension in Dahl salt-sensitive rats. Hypertens Res 2007; 30: 185-193.
14. Rose GA, Blackburn H. Cardiovascular survey methods. Monogr Ser World Health Organ 1968; 56: 1-188.
15. Miller SA, Dykes DD, Polesky HE. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16: 1215.
16. Bunce M, Fanning GC, Welsh KI. Comprehensive, serologically equivalent DNA typing for HLA-B by PCR using sequence-specific primers (PCR-SSP). Tissue Antigens 1995; 45: 81-90.
17. Cermakova Z, Petrkova J, Arakelyan A et al. The MCP-1 -2518 (A to G) single nucleotide polymorphism is not associated with myocardial infarction in the Czech population. Int J Immunogenet 2005; 32: 315-318.
18. Chrysohoou C, Pitsavos C, Panagiotakos DB, Skoumas J, Stefa-nadis C. Association between prehypertension status and inflammatory markers related to atherosclerotic disease: The ATTICA Study. Am J Hypertens 2004; 17: 568-573.
19. Sesso HD, Buring JE, Rifai N et al. C-reactive protein and the risk of developing hypertension. JAMA 2003; 290: 2945-2951.
20. Chen XL, Tummala PE, Olbrych MT, Alexander RW, Medford RM. Angiotensin II induces monocyte chemoattractant protein-1 gene expression in rat vascular smooth muscle cells. Circ Res 1998; 83: 952-959.
21. Tian N, Gu JW, Jordan S et al. Immune suppression prevents renal damage and dysfunction and reduces arterial pressure in salt-sensitive hypertension. Am J Physiol Heart Circ Physiol 2007; 292: H1018-1025.
22. Nakagawa T, Kang DH, Ohashi R et al. Tubulointerstitial disea se: role of ischemia and microvascular disease. Curr Opin Nephrol Hypertens 2003; 12: 233-241.
23. Kim MP, Wahl LM, Yanek LR, Becker DM, Becker LC. A mo nocyte chemoattractant protein-1 gene polymorphism is associated with occult ischemia in a high-risk asymptomatic population. Atherosclerosis 2007; 193: 366-372.
24. Alonso-Villaverde C, Coll B, Parra S et al. Atherosclerosis in patients infected with HIV is influenced by a mutant monocyte chemoattractant protein-1 allele. Circulation 2004; 110: 2204-2209.
25. Tabara Y, Kohara K, Yamamoto Y et al. Polymorphism of the monocyte chemoattractant protein (MCP-1) gene is associated with the plasma level of MCP-1 but not with carotid intima-media thickness. Hypertens Res 2003; 26: 677-683.
26. Bataillard A, Renaudin C, Sassard J. Silica attenuates hypertension in Lyon hypertensive rats. J Hypertens 1995; 13: 1581-1584.
27. Dorffel Y, Latsch C, Stuhlmuller B et al. Preactivated peripheral blood monocytes in patients with essential hypertension. Hypertension 1999; 34: 113-117.
28. Niskanen L, Laaksonen DE, Nyyssonen K et al. Inflammation, abdominal obesity, and smoking as predictors of hypertension. Hypertension 2004; 44: 859-865.
29. Davey Smith G, Ebrahim S. Mendelian randomization': can genetic epidemiology contribute to understanding environmental deter minants of disease? Int J Epidemiol 2003; 32: 1-22.
30. Oshima S, Ogawa H, Hokimoto S et al. Plasma monocyte chemoattractant protein-1 antigen levels and the risk of restenosis after coro nary stent implantation. Jpn Circ J 2001; 65: 261-264.
31. Bucova M, Bernadic M, Buckingham T. C-reactive protein, cyto-kines and inflammation in cardiovascular diseases. Bratisl Lek Listy 2008; 109: 333-340.
32. Mosedale DE, Smith DJ, Aitken S et al. Circulating levels of MCP-1 and eotaxin are not associated with presence of atherosclerosis or pre vious myocardial infarction. Atherosclerosis 2005; 183: 268-274.
33. Szalai C, Duba J, Prohaszka Z et al. Involvement of polymorphisms in the chemokine system in the susceptibility for coronary artery disease (CAD). Coincidence of elevated Lp(a) and MCP-1 -2518 G/G genotype in CAD patients. Atherosclerosis 2001; 158: 233-239.
34. Julius S, Nesbitt SD, Egan BM et al. Feasibility of treating prehy pertension with an angiotensin-receptor blocker. N Engl J Med 2006; 354: 1685-1697.
35. Aljada A, Ghanim H, Saadeh R, Dandona P. Insulin inhibits NFkappaB and MCP-1 expression in human aortic endothelial cells. J Clin Endocrinol Metab 2001; 86: 450-453.
36. Manning RD, Jr., Meng S, Tian N. Renal and vascular oxidative stress and salt-sensitivity of arterial pressure. Acta Physiol Scand 2003; 179: 243-250.
37. Manning RD, Jr., Tian N, Meng S. Oxidative stress and antioxi-dant treatment in hypertension and the associated renal damage. Am J Nephrol 2005; 25: 311-317.
38. Sedlmeier E-M, Grallert H, Huth C et al. Gene variants of monocyte chemoattractant protein 1 and components of metabolic syndrome in KORA S4, Augsburg. Eur J Endocrinol 2007; 156: 377-385.
39. Kozma GT, Falus A, Bojszko A et al. Lack of association between atopic eczema/dermatitis syndrome and polymorphisms in the promoter region of RANTES and regulatory region of MCP-1. Allergy 2002; 57: 160-163.
40. Hwang SY, Cho ML, Park B et al. Allelic frequency of the MCP-1 promoter -2518 polymorphism in the Korean population and in Kore an patients with rheumatoid arthritis, systemic lupus erythematosus and adult-onset Still's disease. Eur J Immunogenet 2002; 29: 413-416.
41. Szolnoki Z. Evaluation of the interactions of common genetic mutations in stroke. Methods Mol Med 2005; 104: 241-250